15 Jul Director/PDMR Shareholding

Paris, France and Camberley, UK – 15 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 14 July 2022, Dr Edwin Snape, a Non-executive Director of the Company, transferred 17,919 ordinary shares of €1/15 each in the Company for nil consideration from CIC Market Solutions – Emetteur to JPMorgan Chase Bank, N.A.

Dr. Snape’s beneficial shareholding is unchanged at 17,919 ordinary shares representing 0.03% of the Company’s issued share capital.

https://novacyt.com/wp-content/uploads/2022/07/Novacyt-Directors-Dealings-RNS-Edwin-Snape.pdf